H A Wieland
Overview
Explore the profile of H A Wieland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
471
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wieland H, Hamilton B
Int J Clin Pharmacol Ther
. 2001 Sep;
39(9):406-14.
PMID: 11563688
In industrial nations the most common form of malnutrition is obesity. Obesity is a chronic disease associated with increased morbidity and mortality. Unfortunately, the simplest treatment for obesity, increasing physical...
2.
Cabrele C, Wieland H, Langer M, Stidsen C, Beck-Sickinger A
Peptides
. 2001 Apr;
22(3):365-78.
PMID: 11287091
Neuropeptide Y (NPY) and pancreatic polypeptide (PP) bind to the Y-receptors with very different affinities: NPY has high affinity for the receptors Y(1), Y(2) and Y(5), while PP binds only...
3.
Wieland H, Hamilton B, Krist B, Doods H
Expert Opin Investig Drugs
. 2000 Nov;
9(6):1327-46.
PMID: 11060746
Neuropeptide Y (NPY) is a 36 amino acid amidated peptide which has now emerged as an important regulator of feeding behaviour. Upon intracerebroventricular (icv.) administration, NPY produces a pronounced feeding...
4.
Weiser T, Wieland H, Doods H
Eur J Pharmacol
. 2000 Sep;
404(1-2):133-6.
PMID: 10980271
We previously reported that (S)-N(2)-[[1-[2-[4-[(R,S)-5, 11-dihydro-6(6h)-oxodibenz[b, e]azepin-11-yl]-1-piperazinyl]-2-oxoethyl]cylopentyl]a cetyl]-N-[2-[1, 2-dihydro-3,5(4H)-dioxo-1,2-diphenyl-3H-1,2, 4-triazol-4-yl]ethyl]argininamid, BIIE0246, is a potent and highly selective neuropeptide Y Y(2) receptor antagonist. Neuropeptide Y Y(2) receptors have been proposed to...
5.
Cabrele C, Langer M, Bader R, Wieland H, Doods H, Zerbe O, et al.
J Biol Chem
. 2000 Aug;
275(46):36043-8.
PMID: 10944518
The first Y(5) receptor-selective analog of neuropeptide Y (NPY), [Ala(31),Aib(32)]NPY, has been developed and biologically characterized. Using competition binding assays on cell lines that express different Y receptors, we determined...
6.
Doods H, Gaida W, Wieland H, Dollinger H, Schnorrenberg G, Esser F, et al.
Eur J Pharmacol
. 1999 Dec;
384(2-3):R3-5.
PMID: 10611450
The in vitro biological characterisation of the first potent and selective non-peptide neuropeptide Y Y(2) receptor antagonist, (S)-N(2)-[[1-[2-[4-[(R,S)-5,11-dihydro-6(6h)-oxodibenz[b, e]azepin-11-yl]-1-piperazinyl]-2-oxoethyl] cylopentyl] acetyl]-N-[2-[1,2-dihydro-3,5(4H)-dioxo-1,2-diphenyl-3H-1,2, 4-triazol-4-yl]ethyl]-argininamid (BIIE0246) is reported. BIIE0246 displaced [125I]neuropeptide Y with...
7.
Eckard C, Beck-Sickinger A, Wieland H
J Recept Signal Transduct Res
. 1999 Mar;
19(1-4):379-94.
PMID: 10071772
The Y1-, Y2-, Y4- and Y5-receptor, which belong to the rhodopsin-like G-protein coupled, 7 transmembrane helix spanning receptors, bind the 36-mer neuromodulator NPY (neuropeptide Y) with nanomolar affinity. Synthetic fragments...
8.
Wieland H, Hamilton B, Krist B
Antisense Nucleic Acid Drug Dev
. 1998 Nov;
8(5):435-40.
PMID: 9826270
The concept of exploiting the ribozyme catalytic center for cleaving a specific target RNA transcript was applied to the design of selective ribozymes for the rat Y1, Y4, and Y5...
9.
Wieland H, Engel W, Eberlein W, Rudolf K, Doods H
Br J Pharmacol
. 1998 Nov;
125(3):549-55.
PMID: 9806339
1. The novel Y1-selective argininamide derivative BIBO 3304 ((R)-N-[[4-(aminocarbonylaminomethyl)-phenyl]methyl]-N2-(diphen ylacetyl)-argininamide trifluoroacetate) has been synthesized and was examined for its subtype selectivity, its in vitro antagonistic properties and its food intake...
10.
Wieland H, Willim K, Doods H
Regul Pept
. 1998 Nov;
75-76:263-9.
PMID: 9802418
At least six types of neuropeptide Y (NPY) receptors (Y1-Y6) have been pharmacologically distinguished of which only the Y1, Y2, Y4 and Y5 subtypes have been thoroughly characterized. In order...